• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark

    Reed-Lane Facility Virtual Tour
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Aptamer Extends Collaboration with AstraZeneca
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Reed-Lane

    Aphena Pharma Solutions

    PCI Pharma Services

    Emergent BioSolutions

    Almac Group
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Adare Pharma Solutions

    Cytovance Biologics

    PCI Pharma Services

    Almac Group
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    R&D Outsourcing Trends

    Highly specialized drug products and capacity needs drive increased reliance on contract service providers.

    R&D Outsourcing Trends
    Kristin Brooks, Managing Editor, Contract Pharma10.14.20
    Beginning with research and ending with final drug approval, the research and development (R&D) journey is inherently long, complex and costly. According to researchers at the Tufts Center for the Study of Drug Development, on average it costs $2.6 billion to develop one new medicine, including the cost of failures, and only 12% of new drug candidates that enter clinical trials win U.S. FDA approval. Drug developers large and small are partnering with Contract Development and Manufacturing Organizations (CDMOs) and Contract Research Organizations (CROs) earlier in the development process to help overcome critical challenges and achieve greater efficiencies across the drug development continuum.

    In addition to reducing drug development timelines and costs, there are several pharma and biopharma trends contributing to increased outsourcing of R&D activities. Among them, increasingly complex small molecules and biologics requiring highly specific drug technologies and expertise to handle highly potent and targeted therapies, namely, cell and gene therapies, cytotoxic/Highly Potent Active Pharmaceutical Ingredients (HPAPIs), and antibody drug conjugates (ADCs).  

    Demand for HPAPI development and manufacture continues to grow driven by targeted medicines in the oncology field. Outfitting facilities to handle HPAPIs is an extensive undertaking for pharma companies lacking in-house capabilities and outsourcing to CDMOs is on the rise. As such, there have been continued and substantial investments by CDMOs to expand capacity in this area, such as Lonza, Piramal, MilliporeSigma, and Cambrex, to name a few.

    According to Grand View Research, the global biologics contract development market size was valued at $5.6 billion in 2019 and is expected to grow at a compound annual growth rate (CAGR) of 8.8% from 2020 to 2027.1 The associated services include cell line development, upstream and downstream processes, analytical/bioanalytical methods, formulations and quality assessment, and regulatory assistance.

    The growing number of biologics in development is driving demand for high-tech development and manufacturing solutions. Most biologics are exceedingly complex and cannot be fully distinguished by science alone, and as such, are often characterized by their manufacturing processes.

    The same can be said for manufacturing cell and gene therapies, which is complex and expensive. There are many challenges that must be overcome to ensure a therapy is safe, effective, and scalable. Unlike traditional drugs, the manufacturing process itself is essentially the product. With a shortage of available manufacturing capacity in the cell and gene therapy space, CDMOs have made substantial investments in bolstering manufacturing capabilities. For example, Lonza built a 300,000-sq.-ft. facility near Houston, TX in 2018 dedicated cell and gene therapy manufacturing—among the largest in the world. 

    The FDA anticipates receiving more than 200 regenerative INDs in 2020 and predicts that they will be approving 10 to 20 cell and gene therapies a year by 2025, based on an assessment of the current pipeline and clinical success rates of these products.2

    Additionally, ADCs are an emerging class of drugs designed to target and destroy cancer cells while preserving healthy cells. While there are only nine ADCs currently approved globally, the market is growing and is expected to reach $15 billion by 2030.3 Unsurprisingly, they too present a unique set of challenges. Their development is complex, requiring stringent containment infrastructure, expertise in several different technologies for small and large molecules, as well as analytical capabilities. Due to these challenges, more than 70 percent of ADC projects are outsourced to CDMOs.4

    The following offers perspectives from CDMOs and CROs embedded today’s R&D landscape, from sourcing APIs to drug development, clinical services and manufacturing. Inevitably, the impact of COVID-19 further plays a role in shaping current drug development strategies and outsourcing.

    Pharma & Biopharma Trends
    Partnering earlier in the drug development process as part of an effort to create efficiencies is growing trend. Dan Bowles, Senior Director, Chemical Development, Cambrex said, “Over time, contract research and manufacturing organizations feel the effects of trending markets, specifically the willingness (or aversion to) for clients to source R&D activities for assets earlier in the development cycle.
    Examples of activities that might be investigated earlier in the API process development cycle include: structural elucidation of key impurities, removing class I and II solvents, hazards analysis, removal of column chromatography, and efforts toward overall cost reduction and process efficiency. Additionally, CRO/CDMOs have observed a significant increase in the number of partnerships, licensing agreements, and M&A activities associated with programs in early development over the last few years.”

    For service providers, addressing pharma/biopharma drug development challenges across various platforms is at the core of their existence. Wilbert Frieling, Corporate Senior Vice President, Global Discovery Services, Charles River, said, “Biopharma companies are having to differentiate their pipelines and diversify into multiple modalities with ever increasing complex science – in addition to the demand to reach clinic as fast and as safely as possible. Now more than ever, the CRO industry must closely align with clients, have greater technical depth to understand the complexities they face and begin to introduce new innovative technologies to speed up the delivery of the all-important robust clinical therapeutics.”

    Further contributing to the surge in outsourcing, COVID-19 and the ensuing restrictions it placed on the pharma industry necessitated extra capacity and capabilities on a global scale. Dr. Frieling added, “Unsurprisingly, many of the changes that we’ve seen in the biotech and pharma industry this year have been related to COVID-19. We are seeing strategic outsourcing trending upward and now with a global pandemic in the picture, we’re seeing a requirement for more diversification. A more diverse model, ideally with a global footprint, helps mitigate costs and protect the business from any bottlenecks that could result from a risky situation, such as COVID-19.”

    New therapeutic modalities, including those to fight COVID-19, require unique discovery and development strategies that go beyond traditional approaches. According to Dr. Frieling, “Advanced medicines, including cell and gene therapy, gene editing, CAR-Ts, and second-generation oligonucleotides, require scientists to rethink previous drug development models and consider a path from target validation to the clinic that is unique to each program.”

    During this critical time, it has become essential to leverage expertise, specialized capabilities, know-how and technologies to help advance these programs in a fast paced and rapidly changing environment.

    August Bioservices recently completed a survey of pharma and biopharma professionals that procure outsourced R&D services. According to the company’s Vice President of Marketing, Cary Martin, “Respondents conveyed a strong desire for potential partners to have deep clinical expertise in their areas of inquiry – for example, with specific proteins, disease states and oncology tumor types. We’re also seeing a rapidly increasing demand for expert-driven fragment-based drug discovery (FBDD) methods. This approach has gained traction in recent years because, while the affinities of potential hits from a fragment screen are lower compared to those achieved with drug-like molecules, the incidence of a hit is orders of magnitude higher.” 

    He added, “On the contract manufacturing side, we’re seeing increased demand for flexible project plans and manufacturing schedules. With the uncertainties introduced by COVID-19, customers want to make sure they choose a partner that can flex with them.”

    Motivators for Outsourcing in Today’s Market   
    Drug complexity that requires specialty drug product capabilities, access to capacity and expertise are among the major motivators behind outsourcing today. According to Wilbert Frieling of Charles River, the biggest motivators are speed, flexibility and risk reduction. “Each of these help pharma companies achieve their goal of getting a therapy to market as fast as possible, without driving up the cost or sacrificing patient safety. Pharma companies that are working with CROs rely on the expertise and breadth of resources that they supply. As they continue to expand and diversify their pipelines, working with a proven partner can open the opportunity to continue to engage with them in other ways,”  Dr. Frieling said.

    Some sponsors, small and large, lack the internal capabilities in early development. Dan Bowles at Cambrex said, “Many of our large pharma clients do not have the infrastructure to handle all their early development work in-house, so much of that work can be handled in an outsourced partner’s facilities. Furthermore, many small to mid-pharma clients are choosing to navigate the drug development process virtually, completing the majority of their work almost exclusively through outsourcing. These clients rely on their partner’s expertise and resources to build a robust product portfolio. A significant portion of clients have returned their programs back to domestic suppliers based on the global economy and political landscape.”

    As the science of drug development has become more complex, so too has conducting clinical trials. Sponsors increasingly rely on CROs for guidance throughout the development process. According to Costa Panagos, President, Research and Development Operations at IQVIA, “The explosion of scientific innovation has a profound impact on how to execute clinical trials, including careful protocol design, as well as logistics and site operations considerations, for example. As a service provider, you need specialized skills to operate successfully in these new models. Obviously, drug development experience is critical, but scientific expertise and a consultative mindset are increasingly important when constructing novel trial designs. Many sponsors only work on several of these types of trials a year, while we deliver these services hundreds of times a year.”

    Sponsors increasingly value expertise as well as scalable processes and technologies. For example, in the cell and gene therapy space, running clinical trials requires coordinating cell collection, therapy manufacture and therapy infusion. CROs also have the ability to make near real-time modifications to aspects of the design based on data from subjects. 

    Additionally, sponsors are outsourcing to help mitigate increasing drug development costs by leveraging flexible service models. Costa Panagos of IQVIA added, “Sponsors are increasingly embracing evolving engagement models such as functional service provision (FSP) and so-called full-service/FSP hybrids to deliver new medicines to market. An FSP partnership in particular allows the sponsor to maintain better control of resourcing and managing the ebb and flow of demand as a program or portfolio progresses through its lifecycle.”

    Leveraging the latest technologies is also a key factor in outsourcing, whether the R&D or manufacturing stage, and beyond. Cary Martin of August Bioservices said, “It all comes down to this – on a micro level, are you the partner who can successfully advance me to the next step in the process, and, on a macro level, can you get me from initial idea to ownable, druggable IP in the most efficacious way possible? Our clients have told us they really value our data-driven approach and ability to be both proactively planful and nimbly responsive on the drug discovery and drug development path. Whether we are using SPR, ITC, MassSpec or other leading-edge technologies, we keep our clients informed up-to-the-minute and we’re quick to report hits, misses and recommended next steps. In short, customers truly appreciate our ability to think alongside them and think ahead for them.” 

    Manufacturing and packaging support is also key. Cary Martin added, “When it comes to our cGMP non-sterile and bulk manufacturing, customers appreciate the services we can offer in addition to our aseptic fill and finish, such as labeling, packaging and kitting, product storage, as well as support services that include regulatory support, supply chain management and quality assurance and validation.”

    For pharma/biopharma companies, getting products to market is the end game, an undertaking fraught with challenges. Timelines need to be shorter and efficiencies met. Scott Carpenter, Vice President, Marketing & Partner of Innovation at Formulated Solutions, LLC said, “Outsourcing continues to grow as brand owners seek companies that can deliver new product innovation along with high quality finished goods, both with increasingly shortened production lead times. In today’s R&D space, the standard models of yesteryear are no longer applicable and abbreviated lead-times are often becoming just as valuable as cost effective, reliable supply. Those that can deliver on these needs, while maintaining a spotless regulatory record, will find themselves in high demand.”

    Sought After Services
    Service providers are seeing increased demand for drug development services across the gamut, from target identification to lead optimization and IND studies to manufacture of clinical trial materials, and from all sectors, from big pharma/biopharma, to small pharma and virtual companies.

    According to Dan Bowles at Cambrex, “We have noticed a surge in requests from a portion of our client base for later phase analytical methods for early clinical development targets, i.e. ‘buying-up’ the analytical package at-risk. We are also seeing more requests for final-form crystallization studies and polymorph screening, as well as a high demand for fully vetted safety profiles, as well as a push for flow chemistry alternatives to complex batch chemistry problems.”

    With capacity at larger CDMOs increasingly limited as a result of COVID-19, smaller pharma/biopharma companies are competing in the market for services. According to Cary Martin of August Bioservices, “We are seeing a surge in requests for drug manufacturing services and, almost as strongly, for custom drug development services. Nearly 60% of responses from our survey are coming from self-identified small pharma/biotech and start-up/ventures. This stands to reason given the perceived trickle-down effect of less capacity being available at the larger CDMOs due to COVID-19. In turn, the smaller and start-up companies are having a harder time finding a partner that fits their parameters. This is a terrific opportunity for CDMOs that have expertise in drug discovery, custom drug development and available capacity to accommodate clinical manufacturing programs in a variety of formulations – injectable liquids, creams, ointments.”

    In the CRO space, data analytics has become an indispensable tool and the impact of COVID-19 has necessitated greater adoption of patient-centric clinical trials, the digitalization of data collection, and remote trial execution. Costa Panagos of IQVIA, said, “The services are matching the trends we see. They are looking for technology and analytics (e.g., AI/ML) to accelerate and improve their trials. And now, with COVID-related challenges, we are seeing a spike in virtual and decentralized trials, telehealth, supply chain, and direct-to-patient and other services that will keep development going across all therapeutic areas. We strongly believe patient-centric technologies and approaches will be a viable solution beyond this global crisis.”

    Global Marketplace
    With respect to R&D outsourcing there continues to be a need for CDMOs and CROs to have a global presence, however we’re also seeing a return to local and/or established markets as well. Wilbert Frieling of Charles River noted, “With COVID-19 not yet behind us, companies are reevaluating risk and the ways they can mitigate it for a second wave, or another global issue that may arise. We see a continued desire to outsource research, but are finding that a big component of this assessment is the geographic footprint of the partners that pharma companies are choosing to work with.”

    Quality concerns have long been cited as a concern of global sourcing propelling a trend to return to domestic providers. The pandemic is further fueling the push to procure drug substance closer to home. Dan Bowles at Cambrex said, “We have observed an increased number of clients returning to domestic suppliers over recent years, and that seems to have further escalated over the last two years in particular. Many have experienced poorer than desired service on previous campaigns abroad and most are willing to pay a domestic premium to avoid many of the pitfalls associated with doing business in a global market. Additionally, many clients push to source raw materials manufacture domestically because of COVID-19 related supply chain issues.” 

    In the face of restrictions placed on industry as a result of the global pandemic, CDMO support has never been more crucial. Scott Carpenter of Formulated Solutions said, “As major pharma labs are either closed or subjected to reduced on-site staffing protocols, we are seeing a rapid increase in R&D outsourcing. In some cases, we are seeing major pharma companies looking to co-develop new products with an external CDMO chosen to supplement the efforts or their own internal R&D team. Concurrently, we are seeing marked increases in the utilization of external innovation teams, where CDMOs are being approached to provide full turn-key product ideation, development, and manufacturing support. This is an exciting time for the CDMO model, and a time we are uniquely and deliberately designed to support.”

    COVID-19 is further driving the domestic trend as an important consideration for sponsors. According to Cary Martin of August Bioservices, “We are seeing an increased interest in bringing manufacturing back to the U.S.  In our survey, 81% of respondents said they are either actively looking or will be looking for a new CRO/CDMO partner within the next 12 months. That tells me there are specific outsourcing needs that are not being met. I believe companies with U.S.-based clinical manufacturing capabilities, drug discovery and development expertise and responsive clinical teams, are well positioned to successfully address those needs in a meaningful way.”

    In summary, specialty drug product capabilities are in great demand in today’s R&D realm. Reliance on service providers with the necessary expertise will likely continue to grow. For CDMOs and CROs, adapting, innovating and providing support services is what they do. 

    References:
    1. https://www.grandviewresearch.com/industry-analysis/biologics-contract-development-market
    2. https://www.fda.gov/news-events/press-announcements/statement-fda-commissioner-scott-gottlieb-md-and-peter-marks-md-phd-director-center-biologics
    3. “Antibody-Drug Conjugates Market to Be Worth $15bn by 2030.” European Pharmaceutical Review, 30 Aug. 2019, www.europeanpharmaceuticalreview.com/news/98037/antibody-drug-conjugates-market-15bn-2030/
    4. Roots Analysis Private Ltd. ADC Contract Manufacturing Market, 2015-2025. August 2015, www.adc.expert/2mNns33
    Related Searches
    • R&D
    • Drug Development
    • Drug Discovery

    Related Features

    • Clinical Trials | Information Technology | R&D
      Decentralized Trials Fuel AI Revolution in Clinical Research

      Decentralized Trials Fuel AI Revolution in Clinical Research

      The life sciences industry is giving clinical a full makeover, dramatically improving how new therapeutics are developed.
      Nick Moss, Vice President of Analytics and Machine Learning, Medable 11.17.20

    • Biologics, Proteins, Vaccines | Biosimilars | Drug Development
      Biopharma Contract Manufacturing: Robust Growth Ahead

      Biopharma Contract Manufacturing: Robust Growth Ahead

      The biopharmaceutical contract manufacturing market is projected to reach $6.3 billion in 2020, and it will continue to grow over the next five years.
      William Downey, HighTech Business Decisions 11.17.20

    • Drug Development | Preclinical Outsourcing
      Preclinical Planning for Successful Drug Development

      Preclinical Planning for Successful Drug Development

      When the preclinical pressure is on, appropriate planning can make sure timelines are achievable.
      Mingyi Trimble, WuXi AppTec 09.09.20


    • APIs | Drug Development | Risk Management
      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-Molecule Drug Development: Advantages of an Integrated, Phase-Based Approach

      Small-molecule drug development has become more complex and challenging, leading to greater reliance on CDMOs.
      Sarah Bethune, Cambrex 09.09.20

    • Biologics, Proteins, Vaccines | Drug Development | Regulatory Affairs
      Expediting a COVID-19 Vaccine: FDA Approval Process

      Expediting a COVID-19 Vaccine: FDA Approval Process

      The pressures of the pandemic are pushing sponsors and FDA to look at both efficacy and speed in developing a vaccine.
      Kristin Brooks, Managing Editor 09.09.20

    • Drug Development | Regulatory Affairs
      Guidelines in Toxicology: A Blessing and a Curse

      Guidelines in Toxicology: A Blessing and a Curse

      A look at the evolution of drug development regulatory guides.
      Sarah Gould, Senior Principal Scientific Advisor, Charles River 09.16.19


    • Drug Discovery
      Drug Discovery Technology Trends

      Drug Discovery Technology Trends

      Combining native mass spectrometry with fragment-based drug discovery in medicinal chemistry
      Sally-Ann Poulsen, Professor of Chemical Biology, Griffith Institute for Drug Discovery (GRIDD), Griffith University 09.16.19

    • Drug Development
      Flex Your Outsourcing Model to Maximize Drug Development

      Flex Your Outsourcing Model to Maximize Drug Development

      How to choose—and optimize—combinations of service models to fit your needs.
      Timothy King, Executive Director, Functional Service Partnerships (FSP), PPD 09.16.19

    • Biologics, Proteins, Vaccines | Drug Delivery | Drug Development
      Knowledge Sharing: Biologics Development and Delivery

      Knowledge Sharing: Biologics Development and Delivery

      The increasing importance of sharing information to build awareness and better manage the complexities of drug development.
      Fran L. DeGrazio, Vice President of Scientific Affairs and Technical Services, West Pharmaceutical Services 09.16.19


    • Drug Development
      Improving Your Development Program

      Improving Your Development Program

      Seven lab science trends driving the future of drug development.
      Jenifer Vija, Liam Moran, Chris Loosbroock and Eric Snyder, Charles River 05.07.19

    • Drug Development
      Technical Advantages of Continuous Flow Chemical Synthesis

      Technical Advantages of Continuous Flow Chemical Synthesis

      Continuous flow chemistry is known for its ability to handle hazardous reactions safely, but can also unlock many other technological benefits.
      Shawn Conway, Engineering R&D Director, Cambrex High Point 04.05.19

    • Drug Development | Preclinical Outsourcing
      Early Development Trends

      Early Development Trends

      Catalent’s president of oral drug delivery, Jonathan Arnold, talks trends and challenges in the early phases of drug development.
      Tim Wright, Editor, Contract Pharma 03.06.19


    • Drug Development
      Future Trends in the CDMO Space

      Future Trends in the CDMO Space

      And how to navigate them for successful drug development
      Guillaume Plane, Global Development and Marketing Manager, BioReliance End-to-End Solutions, MilliporeSigma 01.25.19

    • APIs | Cytotoxics and High Potency Manufacturing | Drug Development
      CDMOs On The Rise

      CDMOs On The Rise

      Tracking growth and strategies in the CDMO business
      Michel Le Bars, Managing Partner, Kurmann Partners AGe 01.25.19

    • Drug Development | Formulation Development
      Abuse Deterrent Formulations

      Abuse Deterrent Formulations

      A look at opioid abuse in North America and formulations to help avoid an epidemic.
      Damon Smith, Richard Dart and Christopher Hirst 11.13.18

    Trending
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • BMS Expands Cell Therapy Manufacturing Capabilities
    • Reed-Lane Facility Virtual Tour
    • Matica Biotechnology Breaks Ground On Cell And Gene Therapy Site
    • Genesis Drug Discovery & Development Acquires Integrated Analytical Solutions
    Breaking News
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    • Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    • Aptamer Extends Collaboration with AstraZeneca
    • Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Thymoquinone Inhibits Viral Infection in In Vitro Settings, New Study Finds
    IFT Transitions 2021 Annual Event to Digital Experience
    NY Federal Judge Enters Permanent Injunction Against Dietary Supplement Manufacturer
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President and COO
    Ashland Completes Expansion and Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    Cretex CFO Announces Retirement
    New AI-Based Tool Developed for Coronary Artery Analysis, Intervention Planning
    First Reported Use of Pulse Biosciences' CellFX System
    Contract Pharma

    Latest Breaking News From Contract Pharma

    AGC Biologics Expands Cell and Gene Facility in Italy
    Celonic to Boost Cell & Gene Therapy Production
    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    Ulta Beauty Opens in Herald Square
    Elizabeth Arden Taps Sui He as Global Brand Ambassador
    Natura &Co Outperforms the Global Market in Q4 2020
    Happi

    Latest Breaking News From Happi

    What You're Reading on Happi.com
    Indie Beauty Innovators Wanted
    Cosmetic Chemists Seek Mentors
    Ink World

    Latest Breaking News From Ink World

    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Hydrocarbon Solvents Market to Surpass $8.1 Billion by 2030
    Access Direct Mail Doubles Revenue with SCREEN's Truepress Jet520HD
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Arjobex America welcomes Maggie Naberezny to sales team
    Henkel publishes 30th Sustainability Report
    Avery Dennison Smartrac launches new Circus Pro inlays
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    FPInnovations Develops Biodegradable Mask
    Sani Professional Sanitizing and Disinfecting Products Approved by EPA
    Autefa Solutions Offers Fully Automated Line for Protective Mask Production
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Bioventus Appoints Managing Director, China and Asia Pacific
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Printed Circuit Board Market Projected to Reach $69.32 Billion by 2027
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login